FAKTOR OPTIONSSCHEIN - ELI LILLY & CO | Market Closed - Deutsche Boerse AG 01:36:44 2024-05-31 pm EDT | ||
| 1.17 EUR | +0.86% |
|
| 1 month | -17.02% | ||
| 3 months | -28.66% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 24-05-31 | 1.17 | +0.86% |
| 24-05-30 | 1.16 | -3.33% |
| 24-05-29 | 1.2 | -0.83% |
| 24-05-28 | 1.21 | +4.31% |
| 24-05-27 | 1.16 | -2.52% |
Delayed Quote Deutsche Boerse AG
Last update May 31, 2024 at 01:36 pm EDT
More quotesStatic data
| Product type | Exotic Products |
|---|---|
| Buy / Sell | CALL |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | UBS |
| WKN | UL7013 |
| ISIN | DE000UL70138 |
| Date issued | 2023-09-07 |
| Strike | 1,087 $ |
| Maturity | Unlimited |
| Parity | 214.38 : 1 |
| Emission price | 5.05 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 6.28 € |
|---|---|
| Lowest since issue | 1.13 € |
| Spread | 0.02 € |
| Spread % | 1.71% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
820.3
USD
Average target price
852.5
USD
Spread / Average Target
+3.92%
- Stock Market
- Certificates
- Certificat
